Nippon Shinyaku Co. Ltd. has announced a significant development in the treatment of Mucopolysaccharidosis II (MPS II), also known as Hunter syndrome. The U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application for RGX-121 (clemidsogene lanparvovec), an investigational gene therapy developed by REGENXBIO. This potential first-in-class therapy aims to address the underlying genetic cause of MPS II by introducing the IDS gene to inhibit long-term disease progression. Nippon Shinyaku, through its subsidiary NS Pharma, Inc., will hold exclusive commercialization rights in the U.S. and Asia, including Japan, upon approval. The BLA submission is supported by promising results from the Phase I/II/III CAMPSIITE trial. Nippon Shinyaku continues to focus on rare disorders, aligning with its mission to help people lead healthier, happier lives.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.